Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company's clinical programs include clinical studies of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor in a range of indications. It has completed Phase III clinical trial of fostamatinib in chronic immune thrombocytopenia (ITP). The Company is conducting a Phase II clinical study with fostamatinib in autoimmune hemolytic anemia (AIHA) and a Phase II clinical study for IgA nephropathy (IgAN). In addition, the Company has two oncology product candidates under development. The Company's product pipeline also includes R348, which is a topical ophthalmic Janus kinase (JAK)/SYK inhibitor indicated for patients with ocular graft-versus-host disease (GvHD). R348 reduces inflammation and limits the damage to the eye tissue caused by the disease.
